Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on November 9, 2016. The report discloses the issuance of a press release announcing financial results for the third quarter ended September 30, 2016. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the announcement of third-quarter results without summarizing the comparative data in the text provided.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information is furnished but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2016) for actual financial figures and operational highlights.
- Verify the company name discrepancy: The request metadata lists "Neurogene Inc.," but the filing is for "Aquinox Pharmaceuticals, Inc."
- Confirm the specific revenue and net loss figures for the quarter ended September 30, 2016, as they are not present in the 8-K summary text.
- Check the cash position and burn rate details in the attached press release to assess liquidity.